Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | SLC6A7 | Q99884 | 4/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP9 | P14780 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10251800 | 0.87 | RIPK1 (0.38) | RIPK1 | |
| SCHEMBL19190271 | 0.86 | STS (0.39) | GRM2TAAR1RORC | |
| SCHEMBL21310317 | 0.84 | GRM2 (0.40) | GRM2TAAR1RIPK1SLC6A7RORC | |
| SCHEMBL14900527 | 0.80 | GRM2 (0.43) | GRM2TAAR1RIPK1SLC6A7RORC | |
| SCHEMBL18691797 | 0.79 | GRM2 (0.42) | GRM2TAAR1RIPK1SLC6A7RORC | |
| SCHEMBL14890375 | 0.79 | GRM2 (0.42) | GRM2TAAR1RIPK1SLC6A7RORC | |
| SCHEMBL14919044 | 0.79 | GRM2 (0.42) | GRM2TAAR1RIPK1SLC6A7RORC | |
| SCHEMBL19190348 | 0.77 | GRM2 (0.43) | GRM2TAAR1RIPK1SLC6A7RORC | |
| SCHEMBL10253643 | 0.74 | ABCB1 (0.43) | — | |
| SCHEMBL1909822 | 0.73 | USP30 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11174219-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-05-27 | — | — | US | disclosed |
| US-10829438-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174219-B2 | Neprilysin inhibitors | MME, REN, ACE | GRM2 4073/4885TAAR1 595/4885RIPK1 3609/4885 |
| US-10829438-B2 | Neprilysin inhibitors | MME, REN, ACE | GRM2 4073/4885TAAR1 595/4885RIPK1 3609/4885 |
| US-20210155576-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | GRM2 4073/4885TAAR1 595/4885RIPK1 3609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.